DEZ-001: Phase I start

Next month, Dezima will begin a double-blind, placebo-controlled, Danish Phase I trial to evaluate 2 dose levels of TA-8995 for 12 weeks in about 36 asymptomatic subjects with isolated, elevated LPA l...